MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 8, 2007; DOI: 10.1124/mol.106.031682


0026-895X/07/7106-1503-1511$20.00
Mol Pharmacol 71:1503-1511, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow All Versions of this Article:
mol.106.031682v1
71/6/1503    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lerche, C.
Right arrow Articles by Seebohm, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lerche, C.
Right arrow Articles by Seebohm, G.

Chromanol 293B Binding in KCNQ1 (Kv7.1) Channels Involves Electrostatic Interactions with a Potassium Ion in the Selectivity Filter

Christian Lerche, Iva Bruhova, Holger Lerche, Klaus Steinmeyer, Aguan D. Wei, Nathalie Strutz-Seebohm, Florian Lang, Andreas E. Busch, Boris S. Zhorov, and Guiscard Seebohm

Physiology I, University of Tuebingen, Tuebingen, Germany (C.L., K.S., N.S.-S., F.L., A.E.B., G.S.); Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada (I.B., B.S.Z.); Department of Neurology, University of Ulm, Ulm, Germany (H.L.); and Department of Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, Missouri (A.D.W.)

The chromanol 293B (293B, trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chroman) is a lead compound of potential class III antiarrhythmics that inhibit cardiac IKs potassium channels. These channels are formed by the coassembly of KCNQ1 (Kv7.1, KvLQT1) and KCNE1 subunits. Although homomeric KCNQ1 channels are the principal molecular targets, entry of KCNE1 to the channel complex enhances the chromanol block. Because closely related neuronal KCNQ2 potassium channels are insensitive to the drug, we used KCNQ1/KCNQ2 chimeras to identify the binding site of the inhibitor. We localized the putative drug receptor to the H5 selectivity filter and the S6 transmembrane segment. Single residues affecting 293B inhibition were subsequently identified through systematic exchange of amino acids that were either different in KCNQ1 and KCNQ2 or predicted by a docking model of 293B in the open and closed conformation of KCNQ1. Mutant channel proteins T312S, I337V, and F340Y displayed dramatically lowered sensitivity to chromanol block. The predicted drug binding receptor lies in the inner pore vestibule containing the lower part of the selectivity filter, and the S6 transmembrane domain also reported to be important for binding of benzodiazepines. We propose that the block of the ion permeation pathway involves hydrophobic interactions with the S6 transmembrane residues Ile337 and Phe340, and stabilization of chromanol 293B binding through electrostatic interactions of its oxygen atoms with the most internal potassium ion within the selectivity filter.


Received October 19, 2006; accepted March 6, 2007

Address correspondence to: Guiscard Seebohm, Physiology I, University of Tuebingen, Gmelinstr. 5, D-72076 Tuebingen, Germany. E-mail: guiscard.seebohm{at}gmx.de







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics